Abstracts tagged "Diabetes"

Abstract Number: 46 • 2014 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout
Seoyoung C. Kim¹, John D. Seeger², Jun Liu³ and Daniel H. Solomon⁴, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of type 2 diabetes (T2D). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the main…
Abstract Number: 2507 • 2014 ACR/ARHP Annual Meeting
Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret^®)?
Barbara Missler-Karger¹, Hans-Eckhard Langer², Mika Leinonen³ and Björn Pilström⁴, ¹Rheumatology consultant, Cologne, Germany, ²RHIO Research Institute, Düsseldorf, Germany, ³4Pharma AB, Stockholm, Sweden, ⁴TA Inflammation, Swedish Orphan Biovitrum AB, Stockholm, Sweden
Background/Purpose 458 patients with rheumatoid arthritis (RA) and inadequate response to traditional DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist…
Abstract Number: 2306 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines
Timothy J Schmidt^1,2, J Antonio Avina-Zubieta^2,3,4, Eric C. Sayre³, Michal Abrahamowicz⁵, John M. Esdaile^2,6,7 and Diane Lacaille^8,9,10, ¹Arthritis Research Centre of Canada, Richmind, BC, Canada, ²Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁵Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁶Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁷Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁸Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁹Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁰University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of decreased quality of life, and increased mortality in RA. RA is associated with an increased risk…
Abstract Number: 1276 • 2014 ACR/ARHP Annual Meeting
Hyperglycemia and Risk of Osteoarthritis
Mona Walimbe¹, Ann V. Schwartz², Irina Tolstykh², Charles E. McCulloch², David T. Felson³, Cora E. Lewis⁴, Neil A. Segal⁵, Michael C. Nevitt² and Nancy E. Lane⁶, ¹Medicine, UCSF (University of California, San Francisco), San Francisco, CA, ²Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, ⁵Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA, ⁶Internal Medicine, Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA
Background/Purpose Osteoarthritis (OA) is reported to be more prevalent in individuals with diabetes mellitus (DM). Potential etiologies include advanced glycation endproducts, which reduce cartilage integrity,…
Abstract Number: 2758 • 2013 ACR/ARHP Annual Meeting
Quantifying The Risk Of Incident Type II Diabetes Following Oral Glucocorticoid Therapy In Patients With Rheumatoid Arthritis: Association With Dose and Duration Of Use
William G. Dixon¹, Mohammad Movahedi², Marie-Eve Beauchamp³, David W. Ray⁴ and Michal Abrahamowicz³, ¹The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Glucocorticoid (GC) therapy is widely used in patients with rheumatoid arthritis (RA). Its association with incident type II diabetes mellitus (DM) is accepted, but…
Abstract Number: 2762 • 2013 ACR/ARHP Annual Meeting
Rheumatoid and Psoriatic Arthritis Are Not Associated With Higher Risk Of Incident Diabetes Mellitus
Susan Mathew¹, Xiaoqin Tang², H. Lester Kirchner³, Mary Chester M. Wasko⁴ and Androniki Bili¹, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Biostatistics, Geisinger Center for Health Research, Danville, PA, ³Geisinger Center for Health Research, Geisinger Health System, Danville, PA, ⁴West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory conditions that are associated with increased risk of insulin resistance and cardiovascular disease…
Abstract Number: 2360 • 2013 ACR/ARHP Annual Meeting
Incidence Of Diabetes and Effect Of Etanercept and Adalimumab On HbA1c Over 1 Year: Data From a Randomised Trial In Patients With Rheumatoid Arthritis
Paola de Pablo¹, Fiona M. Maggs², David Carruthers³, Abdul A. Faizal⁴, Mark T. Pugh⁵ and Paresh Jobanputra⁶, ¹Rheumatology, University of Birmingham Research Laboratories, Queen Elizabeth Hospital, University of Birmingham, College of Medical & Dental Sciences, Queen Elizabeth Hospital Birmingham, UK, Birmingham, United Kingdom, ²Department of Rheumatology, Queen Elizabeth Hospital Birmingham, UK, Birmingham, United Kingdom, ³Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, UK, Birmingham, United Kingdom, ⁴Department of Rheumatology, Solihull Hospital, Heart of England NHS Foundation Trust, UK, Solihull, United Kingdom, ⁵Department of Rheumatology, Saint Mary's Hospital, UK, Isle of Wight, United Kingdom, ⁶Department of Rheumatology, Queen Elizabeth Hospital Birmingham, UK., Birmingham, United Kingdom
Background/Purpose: Inflammation such as that which occurs in rheumatoid arthritis (RA) is associated with insulin resistance and risk of diabetes mellitus (DM). Some DMARDs including…
Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
W. F. C. Rigby¹, L. Takiya², S. P. Wood³, H. Fan² and T. V. Jones², ¹Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
Abstract Number: 2048 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Glucocorticoids-Induced Diabetes In Patients With Rheumatic Diseases
Takayuki Katsuyama¹, Sayaka Aoki², Ken-ei Sada³, Yuriko Yamamura¹, Haruki Watanabe¹, Eri Katsuyama¹, Mariko Narazaki¹, Noriko Tatebe¹, Koichi Sugiyama¹, Katsue S. Watanabe³, Hiroshi Wakabayashi¹, Tomoko Kawabata¹, Jun Wada⁴ and Hirofumi Makino³, ¹Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, ²Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Background/Purpose: Since the efficacy of glucocorticoids for various rheumatic diseases was reported, glucocorticoids are still one of the important therapeutic agents in the current treatment…
Abstract Number: 1834 • 2013 ACR/ARHP Annual Meeting
Abnormal Collagen Fibers Deposition In The Synovial Joints Is a Characteristic Of The Temporal Evolution Of The Diabetic rats’ Model Induced By Streptozotocin
Priscila C Andrade^1,2, Ana Paula P. Velosa¹, Jymenez Morais¹, Edwin R. Parra³, Cláudia Goldeinstein-Schainberg⁴, Vera L. Capelozzi³ and Walcy R. Teodoro¹, ¹Rheumatology, University of Sao Paulo School of Medicine, São Paulo, Brazil, ²Rheumatology, Faculty of Medicine from University of Sao, São Pauo, Brazil, ³Pathology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Diabetes is a causative factor in joint diseases and amplifies the damage induced by other agents as well. According to an accepted hypothesis, damaged…
Abstract Number: 1806 • 2013 ACR/ARHP Annual Meeting
Association Between Hydroxychloroquine Exposure and Incidence Of Diabetes Mellitus In Systemic Lupus Erythematosus
Michelle Petri¹ and Laurence S. Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Diabetes mellitus is one of the SLICC/ACR Damage Index items and a recognized risk factor for cardiovascular disease and renal failure. In rheumatoid arthritis,…
Abstract Number: 1484 • 2013 ACR/ARHP Annual Meeting
Treatment With The Glucagon-Like Peptide-1 Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis
Catherine Sullivan¹, Gadintshware Gaoatswe², James Gibney³, Marie Louise Healy⁴, Michele Doran⁵, David Kane¹, Donal O'Shea² and Ronan Mullan¹, ¹Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, ²Obesity Immunology Group, Education and Research Centre, St Vincent's University Hospital, UCD, Dublin 4, Ireland, ³Department of Endocrinology, Tallaght Hospital, TCD, Dublin 24, Ireland, ⁴Department of Endocrinology, St James Hospital, TCD, Dublin 8, Ireland, ⁵Rheumatology Dept, St James's Hospital, Dublin, Ireland
Background/Purpose: Glucagon-like peptide-1 (GLP-1) analogues such as liraglutide, which are used for the treatment of type 2 diabetes (T2DM), mimic the action of endogenous incretin…
Abstract Number: 115 • 2013 ACR/ARHP Annual Meeting
Association Between History Of Periodontitis and Risk Of Rheumatoid Arthritis In Individuals With and Without Diabetes Mellitus: A Population-Based Cohort Study
Hsin-Hua Chen^1,2, D.Y. Chen¹ and Nicole Huang³, ¹Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ²nstitute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan, ³Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan
Background/Purpose: To examine whether the association between periodontitis (PD) history and the rheumatoid arthritis (RA) risk differs between individuals with and without diabetes mellitus (DM).Methods:…
Abstract Number: 2614 • 2012 ACR/ARHP Annual Meeting
The Risk of Diabetes in Psoriatic Arthritis and Rheumatoid Arthritis
Maureen Dubreuil¹, Young Hee Rho², Ada Man¹, Yanyan Zhu³, Yuqing Zhang², Thorvardur Love⁴, Alexis Ogdie⁵, Joel Gelfand⁶ and Hyon Choi⁷, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Department of Biostatistics, Boston University School of Public Health, Department of Biostatistics, Boston University School of Public Health, Boston, MA, ⁴Landspitali University Hospital, Reykjavik, Iceland, ⁵Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁶University of Pennsylvania., Philadelphia, PA, ⁷Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The potential impact of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) on the risk of incident diabetes remains unclear. Studies have shown that patients…
Abstract Number: 1228 • 2012 ACR/ARHP Annual Meeting
Contributions of Inflammation, Inactivity, and Low Dose Prednisone Use to Skeletal Muscle Insulin Resistance in Well-Controlled Rheumatoid Arthritis
Hiba Abouassi, Lori Bateman, Gary E. McDaniel, Lorraine Elliott-Penry, Michael Muehlbauer, E. William St. Clair, William E. Kraus and Kim M. Huffman, Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Rheumatoid arthritis (RA) is associated with a high prevalence of insulin resistance. Most prior investigations of insulin resistance in RA have examined fasting glucose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].